NEW YORK
Federal court lifts injunction barring New York from issuing cannabis retail licenses
A federal judge has partially lifted a temporary injunction barring New York regulators from issuing recreational cannabis retail dispensary licenses in five regions of the state, reports High There.
The New York Office of Cannabis Management (OCM) is now able to issue licenses for dispensaries in those regions, however, the injunction has been left in place for the Finger Lakes region.
The decision has been welcomed by New York Gov. Kathy Hochul who stated: “For the first time, New Yorkers in nearly every region of the state will have access to safer, high-quality, adult-use cannabis products. I am committed to ensuring New York continues to lead the nation in our safe and equitable approach to the cannabis market.”
According to the publication, a lawsuit challenging the state’s criteria for issuing Conditional Adult-Use Retail Dispensary (CAURD) licenses continues in the federal court system.
NBA
NBA to allow players to promote, invest in and consume cannabis
A groundbreaking bargaining agreement between the National Basketball Association and its players association would allow players to invest in and promote cannabis companies, reports MJ Biz Daily.
The publication highlights that the proposed seven year agreement, which must be ratified by the union and team governors, would open up a new source of funds for cannabis companies, which have been struggling in the face of a tight funding market.
Paul Haagen, co-director of the Center for Sports Law and Policy at Duke University, told MJ Biz Daily: “Assuming that the rumors are true, and that the new (collective bargaining agreement) will remove cannabis from the list of prohibited substances, it would constitute a belief by the League that public attitudes toward cannabis have changed enough that it is no longer a sufficient issue for the League that it is worth any continued conflict with the players over it.”
LATAM
EXCLUSIVE: LATAM Pharma giant signs landmark supply deal with world’s top cannabinoid producer
In an exclusive report for Benzinga, it has been revealed that Brains Bioceutical, the world’s largest manufacturer of natural cannabinoid APIs, has signed a landmark supply agreement with Prati-Donaduzzi to supply natural EU-GMP CBD API.
The API will be used for their ongoing clinical trials and products approved by Brazil’s Health Regulatory Agency.
Ricky Brar, CEO and Chairperson at Brains Bio., told the publication: “This supply agreement is a landmark moment in the history of the pharmaceutical cannabinoids industry. This outcome is the culmination of respective efforts as leading innovators in the space. This makes Brains Bio an important partner for Prati-Donaduzzi as they continue to lead and pave the way in cannabinoid medicines and cannabinoid science.”
